MAGEB18: A Potential Drug Target and Biomarker for the MAGE Family

Target Name: MAGEB18

NCBI ID: G286514

MAGEB18

MAGEB18: A Potential Drug Target and Biomarker for the MAGE Family

The MAGE family is a well-established superfamily of cytoskeletal proteins that are involved in various cellular processes, including cell adhesion, migration, and signaling. MAGEB18, a member of the MAGE family, has been identified as a potential drug target and biomarker for various diseases. In this article, we will discuss the biology of MAGEB18, its potential as a drug target, and its potential as a biomarker for disease.

Biography of MAGEB18

MAGEB18 is a 18-kDa protein that is expressed in various tissues, including muscle, nerve, and heart. It is a member of the MAGE family, which includes MAGEA1, MAGEA3, MAGEB1, MAGEB5, and MAGEB13. MAGEB18 is characterized by a unique N-terminal domain that consists of a 尾-sheet and a 纬-helices.

MAGEB18 functions as a cytoskeleton-associated protein that is involved in various cellular processes. It plays a role in the regulation of cell adhesion, migration, and signaling. MAGEB18 has been shown to be involved in the regulation of T-cell receptor (TCR) signaling, which is a critical process for the development and activation of T-cells.

Potential Drug Target

MAGEB18 has been identified as a potential drug target for various diseases. One of the main reasons for its potential as a drug target is its involvement in TCR signaling. MAGEB18 has been shown to play a role in the regulation of TCR signaling by interacting with the tyrosine kinase PDGFR-尾.

In addition to its involvement in TCR signaling, MAGEB18 has also been shown to be involved in the regulation of cell adhesion and migration. MAGEB18 has been shown to interact with various cytoskeleton-associated proteins, including N-cadherin and vimentin, which are involved in cell adhesion and migration.

Potential Biomarker

MAGEB18 has also been identified as a potential biomarker for various diseases. One of the main reasons for its potential as a biomarker is its involvement in the regulation of T-cell receptor (TCR) signaling, which is a critical process for the development and activation of T-cells.

MAGEB18 has been shown to play a role in the regulation of TCR signaling by interacting with the tyrosine kinase PDGFR-尾. This interaction between MAGEB18 and PDGFR-尾 has been shown to be involved in the regulation of TCR signaling.

Another potential biomarker for MAGEB18 is its involvement in the regulation of cell adhesion and migration. MAGEB18 has been shown to interact with various cytoskeleton-associated proteins, including N-cadherin and vimentin, which are involved in cell adhesion and migration.

Conclusion

MAGEB18 is a member of the MAGE family that is involved in various cellular processes, including cell adhesion, migration, and signaling. Its unique N-terminal domain, which consists of a 尾-sheet and a 纬-helices, and its involvement in the regulation of TCR signaling and cell adhesion make it a potential drug target and biomarker for various diseases. Further research is needed to fully understand the biology of MAGEB18 and its potential as a drug

Protein Name: MAGE Family Member B18

Functions: May enhance ubiquitin ligase activity of RING-type zinc finger-containing E3 ubiquitin-protein ligases. Proposed to act through recruitment and/or stabilization of the Ubl-conjugating enzyme (E2) at the E3:substrate complex

The "MAGEB18 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MAGEB18 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets